Jennifer Wink, MD
Pulmonary Disease · Lakewood, CONPI 1811957707
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abiomed accounts for 69.8% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $543, 3.1 times the $178 reported in 2019.
Across 23 payments — averaging $47.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$768
- Merck$50
- Pulmonx Corporation$49
- Insmed, Inc.$45
- Boston Scientific$37
- Harmony Biosciences LLC$34
- plus $117 from 7 others
What the payments were for
- Food & beverage$1,08699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 7 | $768 |
| Merck | 3 | $50 |
| Pulmonx Corporation | 1 | $49 |
| Insmed, Inc. | 3 | $45 |
| Boston Scientific | 1 | $37 |
| Harmony Biosciences LLC | 1 | $34 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| AstraZeneca | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$145
How this compares
$1,100 in reported general payments places this provider in the 55th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Lakewood
- Kenneth WeisigerLakewood$11K
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Joshiah GordonPueblo$208K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.